Business Wire

Xilam: H1 2017 Revenue: +67%

Del

Regulatory News:

The Xilam Group (Paris:XIL) posted consolidated H1 2017 revenue of EUR 9.239 million, an increase of 67%. The revenue breakdown is as follows:

In EUR 000   30.06.2017 (1)   30.06.2016   Change
New productions(2)   4,571   4,036   +13.3%
Catalogue   4,652   1,491   +212.0%
Other   16   21   -23.8%
Revenue   9,239   5,548   +66.5%

(1) unaudited data
(2) including subsidies and development

Solid growth

An excellent 1H performance was driven by the two main segments, Catalogue and New Productions.

Catalogue revenue tripled over the period, taking Xilam to the next level of its development. This increase stemmed from significant sales to both TV channels and digital platforms. In particular, sales to digital platforms jumped 149% to account for 40% of Catalogue revenue. Growth on the YouTube platforms is continuing its upward trajectory, with 1.12 billion views.

New Productions also performed well. This segment posted revenue of EUR 4.6 million, an increase of more than 13%, boosted by delivery of the latest episodes of Rolling with the Ronks! and further deliveries from season 5 of Oggy & the Cockroaches .

Strong international growth continues

International sales accounted for more than 67% of H1 revenue, an increase of over 194% during the period, thereby consolidating Xilam’s position as a global leader in the animation market.

Xilam content is now shown in more than 160 countries and in 600 million households.

Xilam has secured a number of major contracts for TV and on the leading digital platforms

On top of a solid revenue performance, the first half also saw the signing of several contracts that will further strengthen Xilam’s growth potential in the coming years:

  • The signing of a global distribution agreement with Amazon for its two flagship series Oggy & the Cockroaches and Zig & Sharko
  • The signing of an agreement with Netflix on three series that are currently in production
  • The signing of a new agreement with the Disney Channel for the broadcast of Oggy & the Cockroaches in Germany

Also in the first half of the year, Xilam signed a master toy licensing agreement with Lansay, which should gradually increase merchandising revenue.

Record full-year 2017 revenue expected

After a successful first half to the year, the pace of programme delivery will increase in the second half, to account for two-thirds of 2017 deliveries. Xilam is confident that it will post record revenue in 2017.

Season 5 of Oggy & the Cockroaches already a success

Global advance sales for the new season of Oggy & the Cockroaches were exceptional, and the first programmes will be launched in the third quarter of 2017, notably on Gulli in France, Discovery in Italy, Disney in Germany and Cartoon Network for the whole of Asia.

The quality of this series, along with the projected global distribution and multi-platform programming, will give the Oggy brand unprecedented exposure.

A step-up in production capacity

The upgraded studios that came on stream in 2016 (in Vietnam, Lyon and Angoulême) are now fully operational, enabling Xilam to confirm its ability to deliver about 350 half hours of programmes in 2017-2020.

New series in development

Production of the Mr Magoo series began in early 2017, and Xilam is currently developing a number of new series, including:

  • Coach me if you can
  • Zig & Sharko 3
  • Rolling with the Ronks! 2
  • Petit Méchant Loup [Little Bad Wolf]
  • The fabulous adventures of prince Moka

Coach me if you can and Zig & Sharko 3 are scheduled to enter production in the second half of 2017.

A stronger, more hands-on management team

To support its expansion, Xilam has strengthened its management structure with the arrival of François Bardoux (CFO), Morgann Favennec (Executive VP Development & Global Sales) and Nicolas Halftermeyer (SVP Marketing and Digital), and the internal promotion of François-Xavier de Maistre (Executive VP Organisation and Human Resources).

About Xilam

Xilam is one of Europe’s leading animation companies, producing and distributing original children’s and family entertainment content in both 2D and 3D formats across TV, film and digital media platforms.

Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and 3 feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons, Rolling with the Ronks! and its first pre-school series, Paprika.

Broadcast in over 160 countries on all the major TV networks, these series are also breaking audience records on all the major digital platforms, including YouTube with over 2.2 billion views in 2016, ranking Xilam as one of the top global content providers in animation.

Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.

Xilam is listed on Euronext Paris / Ticker: XIL / ISIN code: FR0004034072

Xilam is eligible for the PEA-PME investment scheme.

Contact information

Xilam
Marc du Pontavice – Chairman and CEO
François Bardoux – CFO
Tel: (33) 01 40 18 72 00

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i